E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10084457 |
E.1.2 | Term | COVID-19 immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028997 |
E.1.2 | Term | Neoplasm malignant |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the humoral immune response against SARS-CoV-2 at 6 months (+/- 4 weeks) after the 2nd dose of a mRNA anti-SARS-CoV-2 vaccine (baseline assessment). |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the duration of the humoral immune response against SARS-CoV-2 at 6 months (+/- 4 weeks) after the baseline assessment or at 6 months (+/- 4 weeks) after the boost with the 3rd dose, if a 3rd dose of the vaccine is administered until 12 months (+/- 4 weeks) after the 2nd dose by local / national health policy guidelines. - To measure the influence of underlying malignant disease on the magnitude and duration of humoral immune response to vaccination against SARS-CoV-2 at: i) 6 months (+/- 4 weeks) after the 2nd dose; and ii) 6 months (+/- 4 weeks) after baseline assessment or 6 months (+/- 4 weeks) after the boost with the 3rd dose, if a 3rd dose of the vaccine is administered until 12 months (+/- 4 weeks) after the 2nd dose by local / national health policy guidelines. - To evaluate safety of mRNA anti-SARS-CoV-2 vaccine 3rd dose.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Analysis of active humoral and cellular immune responses in vaccinated cancer subjects (version 1.0 - 15/09/2021, included in the main protocol) To explore changes in adaptive immune response against SARS-CoV-2 in cancer subjects vaccinated with anti-SARS-CoV-2 mRNA vaccine with the goal of identifying blood biomarkers of response to vaccination. |
|
E.3 | Principal inclusion criteria |
Subjects must meet all of the following criteria in order to be eligible for this study: 1) Age ≥ 18 years old 2) ECOG performance status ≤ 2 3) Subjects with histologically or cytologically confirmed cancer diagnosis (invasive solid tumour or haematological malignancy) undergoing active systemic cancer treatment at the time of 1st dose of the anti-SARS-CoV-2 mRNA vaccine (such as chemotherapy, immunotherapy, targeted agents, endocrine therapy) in - non-metastatic setting or - metastatic setting (only 1st line therapy )
or undergoing follow-up after confirmed cancer complete remission without active cancer treatment for the last 12 months at the time of 1st dose of the anti-SARS-CoV-2 mRNA vaccine
4) Life expectancy > 6 months 5) Subjects who received the 2nd dose of mRNA platform vaccination against SARS-CoV-2 as per local guidelines within 6 months (maximum until 6 months and 3 weeks) prior to registration. 6) Urine pregnancy test negative for all female subjects of childbearing potential within 7 days prior to subject enrolment. 7) Signed Informed Consent form (ICF) obtained prior to any study related procedure. 8) Subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations. |
|
E.4 | Principal exclusion criteria |
Subjects meeting one of the following criteria are not eligible for this study: 1) Known pregnant and/or lactating women. 2) Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator’s opinion, may interfere with completion of the study. 3) Subjects with active diagnosis of acute leukaemia. 4) Subjects treated with bone marrow transplant < 90 days before received vaccination against SARS-CoV-2. 5) Subjects with a known history of HIV infection. 6) COVID-19 infection in the last 28 days before receiving first dose of vaccination against SARS-CoV-2 and up to subject enrolment. 7) Subjects receiving prolonged and/or high doses of systemic immunosuppressive therapies including corticosteroids during the last 28 days before receiving first dose of vaccination against SARS-CoV-2 and up to subject enrolment.8) Subjects who, for any reason, did not receive the 2nd dose of the anti-SARS-CoV-2 mRNA vaccine. 9) Subjects that received the 3rd dose of anti-SARS-CoV-2 mRNA vaccine prior to study entry. 10) Subject that received any dose of non-mRNA anti-SARS-CoV-2 vaccine platform. 11) Subjects with a known or suspected history of severe adverse reactions associated with a vaccine and/or with severe allergic reaction to vaccine components or anaphylaxis in the past. 12) Subjects who have received any other licensed vaccines for other indications within 28 days prior to the 3rd dose, or who are planning to receive any other vaccine up to 14 days after the 3rd dose of the mRNA anti-SARS-CoV-2 vaccine (28 days for live attenuated vaccines). For influenza vaccination, a shorter interval or simultaneous administration is acceptable. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of subjects that have detectable titers of specific antibody against SARS-CoV-2 spike protein, measured by Elecsys® Anti-SARS-CoV-2 S, at 6 months (+/- 4 weeks) after the 2nd dose of a mRNA anti-SARS-CoV-2 vaccine. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
-The proportion of subjects that have detectable titers of specific antibody against SARS-CoV-2 spike protein, measured by Elecsys® Anti-SARS-CoV-2 S, at 6 months (+/- 4 weeks) after the baseline assessment or at 6 months (+/- 4 weeks) after the 3rd dose if administered until 12 months (+/- 4 weeks) after the 2nd dose per local / national health policy guidelines. - The proportion of subjects that have detectable titers of specific antibody against SARS-CoV-2 spike protein, measured by Elecsys® Anti-SARS-CoV-2 S, by underlying malignant disease, at: i) 6 months (+/- 4 weeks) after the 2nd dose; and ii) 6 months (+/- 4 weeks) after baseline assessment or 6 months (+/- 4 weeks) after the boost with the 3rd dose administered until 12 months (+/- 4 weeks) after the 2nd dose per local / national health policy guidelines. - The proportion of subjects that have detectable titers of specific antibody against SARS-CoV-2 spike protein, measured by Elecsys® Anti-SARS-CoV-2 S, by cohort (specified in section 3), at: i) 6 months (+/- 4 weeks) after the 2nd dose; and ii) 6 months (+/- 4 weeks) after baseline assessment or 6 months (+/- 4 weeks) after the boost with the 3rd dose administered until 12 months (+/- 4 weeks) after the 2nd dose per local / national health policy guidelines. - The proportion of asymptomatic subjects with SARS-CoV-2 positive test, confirmed COVID-19 or severe COVID-19 infection with onset at least 14 days after the 2nd dose in subjects who had been without serologic or virological evidence of SARS-CoV-2 infection up to 14 days after the 2nd dose. Whenever reported in the patient’s charter/dossier, both the viral load and mutant strainsof SARS-CoV-2 related data will be collected in the eCRF for any subjects with SARS-CoV-2 infection. - Safety of 3rd dose of mRNA anti-SARS-CoV-2 vaccine, defined as the frequency, duration and severity of adverse reactions reported according to NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
one arm trial, 3 cohorts of patients |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is declared when all the following criteria have been met: - The trial is mature for the analysis of the endpoints as defined in the protocol, if the trial reaches its endpoints. - The database has been fully cleaned and frozen/locked for the final analysis. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |